Protocol Ledger

NCT05296681 · Phase II · RECRUITING

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Interventional Phase II clinical trial protocol NCT05296681 sponsored by Howard S. Hochster, MD in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-03 Enrollment: 42 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05296681
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05296681
Protocol FieldVerified Registry Value
NCT IdentifierNCT05296681
Consolidated Lead SponsorHoward S. Hochster, MD
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment42 participants (ESTIMATED)
Registered Start Date2022-05-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05296681
Hospital Research SiteLocationSite Profile
Rutgers Cancer Institute of New JerseyNew Brunswick, NJOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI